News & Publications

News

2009-2011

11/06/11	Ocera Therapeutics Presents Data from First Human Studies with OCR-002, an Ammonia Scavenger Evaluated for the Treatment of Hyperammonemia and Hepatic Encephalopathy
08/24/11	Ocera Therapeutics Announces that Data from its Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AST-120 in Non-Constipating Irritable Bowel Syndrome was Published in Alimentary Pharmacology & Therapeutics
12/15/10	Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
05/03/10	Data Presented by Ocera Therapeutics at DDW Demonstrates that Neurocognitive Impairment is Highly Prevalent in Ambulatory Cirrhotic Patients
05/03/10	Ocera Therapeutics Demonstrates Proof of Principle for the Use of AST-120 in the Treatment of Non-Constipating Irritable Bowel Syndrome
04/16/10	Ocera Therapeutics Presents Data on the Prevalence of Mild Hepatic Encephalopathy Defined as Neurocognitive Impairment in Patients with Liver Cirrhosis at EASL Annual Meeting
02/23/10	Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial
11/02/09	Ocera Therapeutics Presents Clinical Data Demonstrating AST-120 Relieves Pruritus in Patients with Liver Cirrhosis at the 60th Annual AASLD Meeting
11/02/09	UCL (University College London) Liver Failure Group Present Two Studies on a Novel Treatment Option (OCR-002) for Complications of Hyperammonemia in Liver Failure at the 60th Annual AASLD Meeting
04/28/09	Ocera Therapeutics Presents Data on AST-120 in Patients with Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting
04/01/09	Ocera and UCL Complete Licensing of Novel Treatment of Acute Hepatic Encephalopathy
03/16/09	Jeffrey D. Bornstein, M.D. Joins Ocera Therapeutics, Inc. as Vice President, Clinical Development and Medical Affairs

02/27/08	M. Scott Harris, M.D.,Joins Ocera Therapeutics, Inc., as Chief Medical Officer
02/22/08	Ocera Therapeutics looks to a future IPO and potential partnerships (FierceBiotech)
02/20/08	Ocera Gets $35.5M Series C for GI Trials with AST-120 (BioWorld Today)
02/20/08	Ocera Therapeutics Closes $35.5 Million Series C Financing
01/07/08	Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
10/15/07	Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
10/08/07	Ocera Therapeutics, Inc. Completes Enrollment in FHAST1 , a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn’s Disease
09/19/07	Ocera Therapeutics, Inc. Initiates Phase 2 Clinical Trial in Irritable Bowel Syndrome
09/19/07	Ocera Therapeutics, Inc. Initiates Phase 2 Clinical Trial in Hepatic Encephalopathy
07/10/06	Ocera Therapeutics, Inc. Raises $12 Million Series B Financing
05/24/06	Ocera Therapeutics Initiates Phase 3 Trial in Fistulizing Crohn’s Disease
03/26/06	Ocera Therapeutics Initiates Phase 2 Trial for Active Pouchitis
03/01/06	Ocera Therapeutics, Inc, Appoints Joseph Davie, M.D., Ph.D., Former Head of Biogen Research to its Board of Directors
01/17/06	Ocera Therapeutics, Inc.,a New Gastrointestinal and Liver-Focused Company, Raises $14.5M in Series A Financing